Israeli vaccine data give boost to policy of delaying booster

22 February 2021

A study in Israel indicates that a single dose of BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) coronavirus vaccine is 85% effective.

While the currently-available vaccines are all approved on a two-dose basis, the data add to a growing body of evidence suggesting that a single dose can also provide a high degree of protection against COVID-19.

The results will be particularly welcome in the UK, where the government has broken with international consensus by delaying the offer of a second dose, in order to maximize the distribution of available stocks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK